Michael Comeaux, MBA

#Spine surgeons, are you looking for navigation at your ASC? Take a listen to our upcoming 7D Surgical webinar!

21

Discover the benefits of Minimally Invasive Spine Surgery with Texas Back Institute. Specializing in advanced techniques, we use small incisions and precise methods to reduce trauma and promote quicker recovery. Whether you're dealing with spondylolisthesis, herniated discs, or other conditions, learn what to expect before, during, and after your procedure: https://bit.ly/3NL5s9y #minimallyinvasivesurgery #spinesurgery #spinehealth #texasback

6

Repswear 101…..20yr old construct removals. At Alliance Medical LLC we always try to get imaging at least 3 days before a revision case to leverage our network to identify the hardware. Sometimes, we fail and cannot identify the hardware. So what’s your move? Hope universal removal set can get it out and deal with the docs frustration then?….bring in multiple companies best guess at it?…give the doctor the excuse ahead of time? What would a surgeon prefer? Curious to hear everyone’s play on this. Side note: there are actually a few docs out there that enjoy the challenge of figuring out how to removal obsoleted hardware. Lali Sekhon, MD PhD MBA Jameil ‘Jay’ Pendleton™ Daniel Tighe Caleb Granger Matt Cieply Joshua Taggart Zavation Medical Products, LLC SeaSpine Orthofix Centinel Spine Highridge Medical Precision Spine Innovasis, Inc. Kyocera Medical Technologies, Inc. Accelus Darkwater Consulting

38

39 Comments

To maximize its benefits and ensure patient safety, it's crucial for practitioners to understand and apply certain fundamental principles in ultrasound, including ALARA (As Low As Reasonably Achievable) and the Mechanical Index (MI). Read more on our blog: https://bit.ly/3SyeZCl

3

BiVACOR® Implants First-in-Human Total Artificial Heart at The Texas Heart Institute as a bridge to heart transplant Houston, Texas, July 25, 2024 – The Texas Heart Institute (THI) and BiVACOR®, a clinical-stage medical device company, announced today the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS). BiVACOR’s TAH is a titanium-constructed biventricular rotary blood pump with a single moving part that utilizes a magnetically levitated rotor that pumps the blood and replaces both ventricles of a failing heart. The first-in-human clinical study aims to evaluate the safety and performance of the BiVACOR TAH as a bridge-to-transplant solution for patients with severe biventricular heart failure or univentricular heart failure in which left ventricular assist device support is not recommended. Following this first implantation completed at Baylor St. Luke’s Medical Center in the Texas Medical Center, four additional patients are to be enrolled in the study. “The Texas Heart Institute is enthused about the groundbreaking first implantation of BiVACOR’s TAH. With heart failure remaining a leading cause of mortality globally, the BiVACOR TAH offers a beacon of hope for countless patients awaiting a heart transplant,” said Dr. Joseph Rogers, President and Chief Executive Officer of The Texas Heart Institute and National Principal Investigator on the research. “We are proud to be at the forefront of this medical breakthrough, working alongside the dedicated teams at BiVACOR, Baylor College of Medicine, and Baylor St. Luke’s Medical Center to transform the future of heart failure therapy for this vulnerable population.” Daniel Timms, PhD, Founder and Chief Technology Officer of BiVACOR said, “I’m incredibly proud to witness the successful first-in-human implant of our TAH. This achievement would not have been possible without the courage of our first patient and their family, the dedication of our team, and our expert collaborators at The Texas Heart Institute. Utilizing advanced MAGLEV technology, our TAH brings us one step closer to providing a desperately needed option for people with end-stage heart failure who require support while waiting for a heart transplant. I look forward to continuing the next phase of our clinical trial.” Heart failure is a global epidemic affecting at least 26 million people worldwide, 6.2 million adults in the U.S., and is increasing in prevalence. Heart transplantations are reserved for those with severe heart failure and are limited to fewer than 6,000 procedures per year globally. Media Contacts: Inquiries related to the BiVACOR: Alexander Romero-Wilson, Health Commerce [email protected]

157

2 Comments

Take a look at the TEX20 diagnostic ultrasound system! Clinicians and trainees can improve the speed and accuracy of assessments and procedures with a wide variety of smart tools. From guidance with transducer placement for clearer imaging to time-saving calculations, the TEX20 Series helps clinicians deliver exemplary care. #CriticalCare #EmergencyMedicine #Anaesthesia

21